Evidence map›Paper›PMID 32327479›Full record

ArticleBMJ open2020

[

Rachel M Glicksman, Ur Metser, John Valliant, Peter W Chung, Neil E Fleshner, Robert G Bristow, David Green, Antonio Finelli, Robert Hamilton, Teodor Stanescu and 9 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03160794 (Phase II Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03160794 nacompletednot on this map

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

TypeinterventionalSponsorUniversity Health Network, TorontoRan2017 to 2025Enrolled150ConditionsPost ProstatectomyArms[18F]DCFPyL PET/MRI scan, Stereotactic Ablative Radiotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Radiology · 2022
    Trial
  2. Review
  3. Article
  4. Review
  5. [European journal of nuclear medicine and molecular imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

Rachel M GlicksmanDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-0555-8754
Ur MetserJoint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
John ValliantCentre for Probe Development and Commercialization, McMaster University, Hamilton, Ontario, Canada.
Peter W ChungDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Neil E FleshnerDepartment of Surgical Oncology, Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Robert G BristowDivision of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester; Cancer Research UK Manchester Institute and Manchester Cancer Research Centre; The Christie NHS Foundation Trust, Manchester, UK.
David GreenDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Antonio FinelliDepartment of Surgical Oncology, Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Robert HamiltonDepartment of Surgical Oncology, Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Teodor StanescuDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Douglas HusseyJoint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
Charles CattonDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Mary GospodarowiczDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Padraig WardeDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Andrew BayleyDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Stephen BreenDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Doug VinesDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
David A JaffrayOffice of the Chief Technology and Digital Officer; Department of Radiation Physics; Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alejando BerlinDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada alejandro.Berlin@rmp.uhn.ca.ORCID 0000-0002-1880-6905
University Health Network · CAMount Sinai Hospital · CACancer Research UK · GBCentre for Probe Development and Commercialization · CASunnybrook Health Science Centre · CAThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe oligometastatic (OM) disease hypothesis of an intermediate metastatic state with limited distant disease deposits amenable for curative therapies remains debatable. Over a third of prostate cancer (PCa) patients treated with radical prostatectomy and postoperative radiotherapy experience disease recurrence; these patients are considered incurable by current standards. Often the recurrence cannot be localised by conventional imaging (CT and bone scan). Combined anatomical imaging with CT and/or MR with positron emission tomography (PET) using a novel second-generation prostate-specific membrane antigen (PSMA) probe, [ METHODS AND ANALYSIS: This ongoing single-institution phase II study will enrol up to 75 patients total, to include up to 37 patients with response-evaluable disease, who have rising prostate-specific antigen (range 0.4-3.0 ng/mL) following maximal local therapies with no evidence of disease on conventional imaging. These patients will undergo [ ETHICS AND DISSEMINATION: Ethics approval was obtained from the institutional Research Ethics Board. All patients will provide written informed consent. [ TRIAL REGISTRATION NUMBERS: NCT03160794.

Indexed as

Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstatic NeoplasmsCanadaClinical Trials, Phase II as TopicHumansMaleNeoplasm Recurrence, Localprostate diseaseradiation oncologyradiology & imaging

Identifiers

PMID32327479
PMCPMC7204865
OpenAlexW3018861031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.